Fritextsökning
Artiklar per år
Innehållstyper
-
Rise and Scantox cease conducting animal testing in Stockholm
Access to in vivo toxicology services is significantly decreasing in the Stockholm area as Rise shuts down animal testing and Scantox reorganizes. ”The costs are high, and demand is weak”, says the division manager at Rise to Life Science Sweden.
-
MSD discontinues development of cancer drugs after trial failures
MSD suspends Phase 3 trials for two drug programs for different forms of cancer after trial failures.
-
Large study on milk: Risky for women but not for men
The risk of ischemic heart disease (IHD) and acute myocardial infarction (MI) increased for women with milk intake levels higher than 2 glasses per day, while no such association was found in men, according to a new large Swedish study.
-
Samuel Lagercrantz: ”Geoffrey Hintons farhågor”
”Ska vi få en så ljus framtid som möjligt där AI används på bästa sätt behövs både de som ser risker med den nya tekniken och de som ser sig som teknikoptimister”, skriver Samuel Lagercrantz i en ledare.
-
The new Swedish life science strategy – “It will consolidate Sweden as a leader”
Clinical trials and precision health are emphasised as key areas in the new national life science strategy.
-
AZ gets approval for drug targeting rare disease – it may reduce cortisone dependence
AstraZeneca’s drug Fasenra gets an expanded indication in the EU and is now approved as a treatment for the rare autoimmune disease known as Churg-Strauss syndrome.
-
Lilly´s Nordic manager on Mounjaro launch in Sweden: "Patients deserve respect"
Another blockbuster diabetes and obesity drug has made its way into the Swedish market – with promises of a stable supply and availability for patients. “What we see is a significant unmet need, so we are expecting to have quite a good welcoming in the market", says Daniel Lucas, Managing Director Nordic Countries at the American pharmaceutical giant Eli Lilly.
-
”The importance of stratification in a statistician’s August kitchen”
Ingrid Lönnstedt writes about an experiment of her own at home and about what lessons can be learned from it, in a science column.
-
Her company is developing a new tablet form obesity drug
Obesity and diabetes are the primary targets of a new tablet treatment under development by Malmö-based Pila Pharma. The company’s ambition is to take on the billion-selling GLP1 analogues. ‘‘Basically, I expect all the beneficial effects that they have, but not the same side effect profile,’’ company founder Dorte X Gram said in an interview with Life Science Sweden.
-
Tre forskare får Nobelpriset i kemi 2024
Årets Nobelpris i kemi går till David Baker, Demi Hassabis och John M. Jumper för att ha lyckats bygga nya proteiner och förutspå proteiners komplexa struktur.
-
This years Nobel prize in medicine – “Changed the understanding of how genes are controlled”
This year’s Nobel Prize in Physiology or Medicine goes to the discovery that small RNA molecules, known as microRNAs, control how genes are regulated. Understanding the mechanism has changed our view of human biology and evolution, says KI Professor
-
Caroline Leksell Cooke ny chef på Elekta
Elekta har rekryterat Caroline Leksell Cooke till ny Senior Vice President och Head of Neuro Solutions. Hon börjar sin nya tjänst den 1 november.
-
Anna Törner: ”Mom, do you think you’ll ever get married again?”
”I realize I’m slowly descending into that familiar statistical rabbit hole, where life’s biggest uncertainties are reduced to point estimates and confidence intervals”, Anna Törner writes in a column.
-
Anna Törner: ”Mamma, tror du att du kommer att gifta om dig?”
”Jag inser att min hjärna är på väg ned i det statistiska kaninhålet, där frågor besvaras med punktskattningar och konfidensintervall.” Det skriver Anna Törner i en krönika.
-
What will be the next big hype after obesity? – An expert panel highlighted their top picks
What will be the next big trend in life science? Everything from Alzheimer’s, Crispr and Omics were highlighted when the issue was debated at this year’s major life science event in Lund.
-
BioArctic moves forward with its candidate for Parkinson’s
BioArctic announces positive early phase study results for its drug candidate for Parkinson’s disease.
-
Anna Törner: Yes, I Am Sick, But Not Weak
”People often say that someone who is ill only has one wish—to get better. But I think that is not true. Someone who is ill also longs to be understood, to be respected, to not have their identity overshadowed by their condition”, writes Anna Törner in a column.
-
Gothenburg, the city of life science – We are ‘Little Boston’
Western Sweden is investing in life science within everything from advanced therapeutic drugs to femtech. At the same time, stakeholders are looking to other industries for inspiration and knowledge.
-
Carl Borrebaeck – professor and serial entrepreneur with a taste for speed
Award-winning cancer researcher, the founder of many listed companies, and constantly in the academic and commercial spotlight for decades. However, Carl Borrebaeck, Professor of Immunotechnology at Lund, is not yet satisfied. “We have a new, potentially super exciting project in the pipeline,” he says.
-
List: The coolest names in biotech
Hairy beasts, volcanic material and space strolling stand out on a US list of the best biotech company names, and on a list of the coolest names for pharmaceuticals, a Swedish, or at least Swedish-British, drug came out on top.
-
Nocebo – the evil twin that makes you feel worse
The placebo effect is well known in healthcare, but not so its opposite: nocebo. “The effect is small, but it can have major repercussions,” says Uppsala researcher Charlotte Blease, co-author of a book on the phenomenon.
-
Hon är ny på Gradientech
Diagnostikbolaget Gradientech har rekryterat AnnaLotta Schiller Vestergren till tjänsten som Chief Commercial Officer.
-
Specific proposals and targets top the universities’ desired priorities
What are the universities’ expectations for the update of the national life science strategy? Life Science Sweden posed the question to representatives from Karolinska Institutet and Sahlgrenska Academy.
-
Venom from the deathstalker carries radiopharmaceuticals to the brain
In order to target cancerous brain tumours with radionuclides, the problematic blood-brain barrier must first be crossed. Life Science Sweden has visited a KI researcher who is trialling an unusual approach ‒ using scorpion venom.